Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 110

Sort by

Sort Order Select

Journal Articles

Pirtobrutinib vs ibrutinib in treatment-naïve and relapsed/refractory CLL/SLL: Results from the first randomized phase III study comparing a non-covalent and covalent BTK inhibitor

Blood (2025) 146 (Supplement 1): 683.

https://doi.org/10.1182/blood-2025-683

Published: 2025

Journal Articles

Prognostic significance of clinical risk models and genomic alterations in Waldenström macroglobulinemia before or after BTK inhibitor era

Weihao Chen, Yuting Yan, Ying Yu, Yuxi Li, Xiong Wenjie, Xinyi Zhang, Tingyu Wang, Wei LIU, Weiwei Sui, Zhen Yu, Mu Hao, Gang An, Dehui Zou, Lugui Qiu, Shuhua Yi

Blood (2025) 146 (Supplement 1): 3593.

https://doi.org/10.1182/blood-2025-3593

Published: 2025

Journal Articles

Efficacy and tolerability of mesutoclax monotherapy in Relapsed/Refractory Mantle Cell Lymphoma patients: High remission rates even in prior BTKi-refractory patients

Blood (2025) 146 (Supplement 1): 887.

https://doi.org/10.1182/blood-2025-887

Published: 2025

Journal Articles

Efficacy and safety of rocbrutinib, the fourth generation bruton's tyrosine kinase inhibitor, in patients with BTK inhibitor pre-treated relapsed or refractory Mantle Cell Lymphoma: Results from a Phase II rock-1 trial

Blood (2025) 146 (Supplement 1): 886.

https://doi.org/10.1182/blood-2025-886

Published: 2025

Journal Articles

Impact of autoimmune hemolytic anemia on prognosis in chronic lymphocytic leukemia patients: A comprehensive retrospective analysis

Liang Wang, Yuting Yan, Lugui Qiu, Tingyu Wang, Shuhua Yi

Blood (2025) 146 (Supplement 1): 2126.

https://doi.org/10.1182/blood-2025-2126

Published: 2025

Journal Articles

A prospective, single-center, single-arm clinical trial of zanubrutinib monotherapy and zfcg combined therapy was given sequentially for the treatment of primary symptomatic CLL/SLL (Stop Trial)

Tingyu Wang, Yuting Yan, Ying Yu, Xiong Wenjie, Rui Lv, Tengteng Yu, Wei LIU, Yan Xu, Weiwei Sui, Wenyang Huang, Shuaishuai Zhang, Qi Wang, Lugui Qiu, Shuhua Yi

Blood (2025) 146 (Supplement 1): 2124.

https://doi.org/10.1182/blood-2025-2124

Published: 2025

Journal Articles

BCMA CAR T-cell therapy in newly diagnosed transplant-ineligible multiple myeloma: An open label, single-arm, phase 2 study (CAREMM-001)

Wenqiang Yan, Chenxing Du, Hesong Zou, Shuaishuai Zhang, Shuhui Deng, Yan Xu, Shuhua Yi, Dehui Zou, Lugui Qiu, Gang An

Blood (2025) 146 (Supplement 1): 2293.

https://doi.org/10.1182/blood-2025-2293

Published: 2025

Journal Articles

A phase I study of HDM2005, a ROR1 targeted antibody-drug conjugate (ADC), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) or classical Hodgkin lymphoma(cHL)

Shuhua Yi, Liping Su, Bingzong Li, Zhiming Li, Zhengming Jin, Ming Jiang, Wenjuan Yu, Zengjun Li, Jun Luo, Wei Yang, Fei Li, Cailing Wang, Hui Wu, Qiang Wang, Bing Yu, Jianghua Chen, June Xu, Lugui Qiu

Blood (2025) 146 (Supplement 1): 1808.

https://doi.org/10.1182/blood-2025-1808

Published: 2025

Journal Articles

Metabolomics profiling and machine learning prediction of efficacy and prolonged cytopenia in patients with large B-cell lymphoma undergoing CAR-T therapy

Hesong Zou, Chen Jia, Wei LIU, Huimin Liu, Yi Wang, Yan Xu, Shuhua Yi, Gang An, Lugui Qiu, Dehui Zou

Blood (2025) 146 (Supplement 1): 1938.

https://doi.org/10.1182/blood-2025-1938

Published: 2025

Journal Articles

Preliminary analysis of orelabrutinib combined with obinutuzumab in the treatment of marginal zone lymphoma (Orion Study)

Rui Lv, Tingyu Wang, Yuting Yan, Tengteng Yu, Xiong Wenjie, Ying Yu, Qi Wang, Shuaishuai Zhang, Hesong Zou, Shuhui Deng, Yan Xu, Dehui Zou, Liang Huang, Gang An, Lugui Qiu, Shuhua Yi

Blood (2025) 146 (Supplement 1): 5379.

https://doi.org/10.1182/blood-2025-5379

Published: 2025

Journal Articles

Preliminary efficacy and safety of golidocitinib in relapsed/refractory T cell and NK cell large granular lymphocyte leukemia

Ying Yu, Yuxi Li, Rui Cui, Tingyu Wang, Yin WU, Chenglu Yuan, Yuqing Chen, Huanling Zhu, Yuting Yan, Wenjie Xiong, Shuhui Deng, Gang An, Lugui Qiu, Shuhua Yi

Blood (2025) 146 (Supplement 1): 3648.

https://doi.org/10.1182/blood-2025-3648

Published: 2025

Journal Articles

Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: The first real-world data from a single Chinese center

Blood (2025) 146 (Supplement 1): 4074.

https://doi.org/10.1182/blood-2025-4074

Published: 2025

Journal Articles

BGB-3111-218: Single-arm, open-label, multicenter study of the Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (zanu) in patients with CD79B-mutated Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

Blood (2025) 146 (Supplement 1): 3684.

https://doi.org/10.1182/blood-2025-3684

Published: 2025

Journal Articles

Mesutoclax (ICP-248) monotherapy or combined with orelabrutinib demonstrates encouraging activity and safety in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Blood (2025) 146 (Supplement 1): 5677.

https://doi.org/10.1182/blood-2025-5677

Published: 2025

Journal Articles

Primary analysis of a multicenter, open-label, phase 2 study of sonrotoclax (BGB-11417) monotherapy in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)

Blood (2025) 146 (Supplement 1): 5666.

https://doi.org/10.1182/blood-2025-5666

Published: 2025

Journal Articles

Promising safety and efficacy of equecabtagene autoleucel (eque-cel) followed ASCT in ultra high-risk multiple Myeloma (UHR-MM) patients: primary real world data from a single center

Blood (2025) 146 (Supplement 1): 2299.

https://doi.org/10.1182/blood-2025-2299

Published: 2025

Journal Articles

Clinical characteristics and prognostic analysis of 52 cases of ALK-positive anaplastic large cell lymphoma

Wen Zhang, Wei LIU, Ting Xie, Tingyu Wang, Xiong Wenjie, Hesong Zou, Yi Wang, Shuhua Yi, Wenyang Huang, Lugui Qiu, Dehui Zou

Blood (2025) 146 (Supplement 1): 7165.

https://doi.org/10.1182/blood-2025-7165

Published: 2025

Journal Articles

Serum free light chain escape before IMWG progression: A predictive marker and a therapeutic opportunity

Blood (2025) 146 (Supplement 1): 4015.

https://doi.org/10.1182/blood-2025-4015

Published: 2025

Journal Articles

Γδ and Αβ T-Cell Large Granular Lymphocytic Leukemia Have Similar Characteristics and Outcomes

Blood (2024) 144 (Supplement 1): 1678.

https://doi.org/10.1182/blood-2024-202457

Published: 2024

Journal Articles

Prognostic Significance of Monoclonal Gammopathy in Chronic Lymphocytic Leukemia Under Different Therapeutic Backgrounds

Yuting Yan, Bolin Yuan, Tingyu Wang, Ying Yu, Weihao Chen, Dandan Shan, Xiong Wenjie, Gang An, Dehui Zou, Lu-Gui Qiu, Qiong Wang, Shuhua Yi

Blood (2024) 144 (Supplement 1): 1861.

https://doi.org/10.1182/blood-2024-204668

Published: 2024

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Pirtobrutinib vs ibrutinib in treatment-naïve and relapsed/refractory CLL/SLL: Results from the first randomized phase III study comparing a non-covalent and covalent BTK inhibitor

Prognostic significance of clinical risk models and genomic alterations in Waldenström macroglobulinemia before or after BTK inhibitor era

Efficacy and tolerability of mesutoclax monotherapy in Relapsed/Refractory Mantle Cell Lymphoma patients: High remission rates even in prior BTKi-refractory patients

Efficacy and safety of rocbrutinib, the fourth generation bruton's tyrosine kinase inhibitor, in patients with BTK inhibitor pre-treated relapsed or refractory Mantle Cell Lymphoma: Results from a Phase II rock-1 trial

Impact of autoimmune hemolytic anemia on prognosis in chronic lymphocytic leukemia patients: A comprehensive retrospective analysis

A prospective, single-center, single-arm clinical trial of zanubrutinib monotherapy and zfcg combined therapy was given sequentially for the treatment of primary symptomatic CLL/SLL (Stop Trial)

BCMA CAR T-cell therapy in newly diagnosed transplant-ineligible multiple myeloma: An open label, single-arm, phase 2 study (CAREMM-001)

A phase I study of HDM2005, a ROR1 targeted antibody-drug conjugate (ADC), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) or classical Hodgkin lymphoma(cHL)

Metabolomics profiling and machine learning prediction of efficacy and prolonged cytopenia in patients with large B-cell lymphoma undergoing CAR-T therapy

Preliminary analysis of orelabrutinib combined with obinutuzumab in the treatment of marginal zone lymphoma (Orion Study)

Preliminary efficacy and safety of golidocitinib in relapsed/refractory T cell and NK cell large granular lymphocyte leukemia

Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: The first real-world data from a single Chinese center

BGB-3111-218: Single-arm, open-label, multicenter study of the Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (zanu) in patients with CD79B-mutated Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

Mesutoclax (ICP-248) monotherapy or combined with orelabrutinib demonstrates encouraging activity and safety in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Primary analysis of a multicenter, open-label, phase 2 study of sonrotoclax (BGB-11417) monotherapy in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)

Promising safety and efficacy of equecabtagene autoleucel (eque-cel) followed ASCT in ultra high-risk multiple Myeloma (UHR-MM) patients: primary real world data from a single center

Clinical characteristics and prognostic analysis of 52 cases of ALK-positive anaplastic large cell lymphoma

Serum free light chain escape before IMWG progression: A predictive marker and a therapeutic opportunity

Γδ and Αβ T-Cell Large Granular Lymphocytic Leukemia Have Similar Characteristics and Outcomes

Prognostic Significance of Monoclonal Gammopathy in Chronic Lymphocytic Leukemia Under Different Therapeutic Backgrounds

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only